US FDA Gives Directions On Navigating Generic 180-Day Exclusivity Maze
Draft guidance sums up agency’s policies for determining exclusivity, clarifies when the clock starts for failure to market.
You may also be interested in...
Trump Administration memo could further delay some US FDA guidance documents already past due under the FDA Safety and Innovation Act; attorneys predict uncertainty about, but no immediate impact on, biosimilar and communications draft guidances released in last few weeks of the Obama Administration.
Pursing legal action against the agency in an area where it is sometimes vulnerable, Par argues that amending its proposed label did not interrupt paragraph IV certification for the firm's colchicine ANDA.
Agency rejects Sandoz’s assertion that the 30-month period for securing ANDA tentative approval under the MMA’s forfeiture provisions begins to run on the date an application is submitted.